Pulmonary arteriovenous malformations (PAVMs) are caused by abnormal direct communications between pulmonary arteries and pulmonary veins without interposition of a capillary bed^(1,2). These uncommon lesions are usually congenital, with approximately 80 to 90% of patients with PAVMs having hereditary hemorrhagic telangiectasia (HHT), whereas the remaining are sporadic cases. Conversely, approximately 15 to 35% of patients with HHT have PAVMs⁽²⁾. PAVMs associated with HHT may cause severe complications that may be prevented by embolization therapy⁽³⁾. Since they are for the most part encountered in HHT population, a screening strategy based on the combined use of contrast echocardiography followed by chest CT scanner examination is usually the proposed diagnostic algorithm to detect PAVMs for preventive treatment HHT patients⁽⁴⁾22,  moreoveruld d in orden to dectect the presence of thrombus formation inside, moreover. Treatment, consisting in PAVMs percutaneous embolization, is challenging even in the most experienced hands⁽⁵⁾Chest CT also plays a role in the follow-up after treatment⁽⁴⁾.

 CT angiography (CTA) is a valuable tool that allows characterization of PAVMs with a detailed three-dimensional (3D) analysis of their angioarchitecture, facilitating treatment planning well in advance and becoming the key follow-up examination in these patients. Besides, contrast-enhanced CT (CECT) provides valuable information that would not be obtained without contrast administration. 

Normal 0 false false false ES-TRAD JA X-NONE

 The increasing use of CTA together with the advent of new materials and improvements in embolization techniques directly impacted in PAVMs management in HHT patients^(2,5-11).It is not our purpose to discuss hereditary hemorrhagic telangiectasia in detail, rather our purpose is to discuss HHT predominantly as it relates to PAVMs, and to provide an update regarding the role of CTA in the mangement of PAVMs in HHT patients.